Agilon Health, Inc. (AGL) faced a significant downgrade this week, as JP Morgan analyst Lisa Gill moved the company’s rating to Underweight on May 4, 2026. This shift reflects broader concerns about the company’s future growth prospects amid a challenging healthcare landscape. For investors, this rating change highlights the need for careful consideration of AGL’s fundamentals, especially in light of its underwhelming performance indicators.
Recent Price Action
As of the latest trading session, AGL stocks are priced at $26.94, marking a decline of $2.64 or approximately 8.92% on the day. Over the last 52 weeks, AGL has experienced a bewildering range with a high of $75.47 and a low of $21. Investors have shown some caution, reflected in a trading volume of 325,399 shares, slightly below the average volume of 330,385. Despite having a market capitalization of $448.81 million, AGL’s low beta of 0.329 suggests minimal market volatility, though recent trading behavior indicates an uptick in nervousness among investors.
[chart type=’price’ value=’AGL’]
Short- and Long-Term Performance
Over the past month, AGL has rebounded impressively with a 45.28% resurgence. This recovery, however, is tempered by a modest 1.75% increase over the last quarter, juxtaposed against a staggering 67% drop over the past year. The weekly volatility rate of 6.92% and monthly volatility of 8.51% suggest that AGL has been subject to significant fluctuations, leaving investors assessing how sustainable its recent gains may be. Notably, the average trading volume over 10 days was 401,163 shares, indicating heightened investor activity, while the three-month average volume stood at 335,246 shares.
[chart type=’performance’ value=’AGL’]
Earnings / Financials
The company’s recent earnings report provides insight into its financial health. AGL posted an actual EPS of -$11.50 against an expected EPS of -$6.75, resulting in a significant negative surprise of 70.37%. This deviation raises questions about the company’s earnings predictability and operational efficiency. To provide context, in the previous quarter, AGL also reported an EPS of -$0.27, missing estimates by a smaller margin of 50%. Such discrepancies in earnings make it crucial for investors to analyze the company’s upcoming strategies and operational changes closely.
[chart type=’income-bar-chart’ value=’AGL’]
Analyst / Consensus View
Following the downgrade by JP Morgan, the consensus sentiment surrounding AGL has shifted. Among a total of five analysts, there are two Buy ratings, one Hold, and two Sell ratings. The average price target has notably fallen to $7.47, with the highest target remaining at $21. The low end of the spectrum presents a stark outlook at $0.85, underscoring the potential for further value erosion. The recent rating by JP Morgan reflects a cautious stance, suggesting that upside potential is limited in the near term.
[chart type=’analyst-ratings’ value=’AGL’]
Stock Grading or Fundamental View
The Stocks Telegraph grading score for Agilon Health, Inc. is currently at 41, indicating a mixed health and investment profile. This score suggests underlying weaknesses in AGL’s financial stability and market performance. A score this low typically reflects concerns about fundamentals, particularly given the recent earnings misses and the company’s struggle to maintain its position in a rapidly evolving healthcare sector.
[chart type=’st-cards’ value=’AGL’]
Conclusion
For investors weighing the potential of Agilon Health, the current environment suggests a cautious approach. The stock is particularly suited for those who adopt a defensive strategy, prepared to navigate considerable risks and uncertainties. Nevertheless, the substantial recent price recovery may attract more speculative investors looking for quick gains in a volatile market. In light of the financial discrepancies, recent rating revisions, and overall market sentiment, AGL warrants close monitoring to ensure that downside risks are adequately managed.